These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 8882962)

  • 1. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasibility and efficacy of an intensive multidrug regimen.
    Bertini M; Freilone R; Vitolo U; Botto B; Ciotti R; Cinieri S; Di Nota A; Di Vito F; Levis A; Orsucci L; Pini M; Rota-Scalabrini D; Todeschini G; Resegotti L
    Leuk Lymphoma; 1996 Aug; 22(5-6):483-93. PubMed ID: 8882962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL).
    Bertini M; Freilone R; Vitolo U; Botto B; Pizzuti M; Gavarotti P; Levis A; Orlandi E; Orsucci L; Pini M
    Ann Oncol; 1994 Dec; 5(10):895-900. PubMed ID: 7535080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CEOP-B alternated with VIMB in intermediate-grade and high-grade non-Hodgkin's lymphoma: a pilot study.
    De Lena M; Ditonno P; Lorusso V; Brandi M; Timurian A; Marzullo F; Ventrella V; Pellecchia A
    J Clin Oncol; 1995 Apr; 13(4):953-60. PubMed ID: 7535844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients.
    Zinzani PL; Gherlinzoni F; Storti S; Zaccaria A; Pavone E; Moretti L; Gentilini P; Guardigni L; De Renzo A; Fattori PP; Falini B; Lauta VM; Mannina D; Zaja F; Mazza P; Volpe E; Lauria F; Aitini E; Ciccone F; Tani M; Stefoni V; Alinari L; Baccarani M; Tura S
    Ann Oncol; 2002 Sep; 13(9):1364-9. PubMed ID: 12196361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen.
    Sawada KI; Sato N; Kohno M; Hannda H; Yasukouchi T; Tanngo M; Hirayama A; Koike T
    Leuk Lymphoma; 1995 Dec; 20(1-2):103-9. PubMed ID: 8750630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cooperative study of epirubicin with cyclophosphamide, vincristine and prednisone (CEOP) in non-Hodgkin's lymphoma.
    Lambertenghi Deliliers G; Butti C; Baldini L; Ceriani A; Lombardi F; Luoni M; Montalbetti L; Pavia G; Pinotti G; Pogliani E
    Haematologica; 1995; 80(4):318-24. PubMed ID: 7590500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial.
    Hainsworth JD; Litchy S; Lamb MR; Rodriguez GI; Scroggin C; Greco FA
    Clin Lymphoma; 2003 Jun; 4(1):36-42. PubMed ID: 12837153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, epirubicin, vincristine, prednisone, bleomycin, etoposide (CEOP-BE) therapy for intermediate- and high-grade non-Hodgkin's lymphomas.
    Mugitani A; Tatsumi Y; Tanaka K; Yasui Y; Inoue T
    Anticancer Res; 1999; 19(4C):3393-7. PubMed ID: 10629625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effective therapy for poor-prognosis non-Hodgkin's lymphoma with 8 weeks of high-dose-intensity combination chemotherapy.
    Waits TM; Greco FA; Greer JP; Johnson DH; Wolff SN; Stein RS; McMaster ML; Hainsworth JD
    J Clin Oncol; 1993 May; 11(5):943-9. PubMed ID: 7683712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermediate and high grade malignant non-Hodgkin's lymphomas: preliminary results using a new combination regimen (EVE-COPEM).
    Battista C; Panza N; Chiurazzi B; Iodice G; Esposito G; Cocorocchio E; Bevilacqua N; Pacilio G
    Biomed Pharmacother; 1993; 47(4):145-54. PubMed ID: 8018826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
    J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
    Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
    J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy (LNHIV-91 regimen) and G-CSF for HIV associated non-Hodgkin's lymphoma.
    Oksenhendler E; Gerard L; Dubreuil ML; Levy Y; Matheron S; Cazals-Hatem D; Chevret S; Clauvel JP
    Leuk Lymphoma; 2000 Sep; 39(1-2):87-95. PubMed ID: 10975387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
    Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma.
    Martelli M; Guglielmi C; Coluzzi S; Avvisati G; Amadori S; Giovannini M; Torromeo C; Mandelli F
    J Clin Oncol; 1993 Dec; 11(12):2362-9. PubMed ID: 7504091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF.
    Errante D; Gabarre J; Ridolfo AL; Rossi G; Nosari AM; Gisselbrecht C; Kerneis Y; Mazzetti F; Vaccher E; Talamini R; Carbone A; Tirelli U
    Ann Oncol; 1999 Feb; 10(2):189-95. PubMed ID: 10093688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [VNCOP-B (etoposide, mitoxantrone, cyclophosphamide, vincristine, predonisolone, bleomycin) therapy in elderly patients with aggressive non-Hodgkin lymphoma--a study of efficacy and safety, final report].
    Ishii K; Yamamoto Y; Shigeki T; Kitayama H; Hayashi K; Hirose A; Ohta T; Mugitani A; Fujino H; Yagi T; Hirai M; Teshima H; Katsurada T; Urase F; Kitajima H
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):39-44. PubMed ID: 15675580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot study. The Adult Lymphoma Treatment Study Group (ALTSG).
    Niitsu N; Okamoto M; Kuraishi Y; Nakamura S; Kodama F; Hirano M
    Eur J Haematol; 2000 Sep; 65(3):188-94. PubMed ID: 11007055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.